Argenx, Calliditas Hit The Ground Running After FDA Approvals

Green Lights For Vyvant and Tarpeyo

20 Dec 2021

Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.

eu flags — Last week was a cause for celebration for two European biotechs bagging US approvals • Source: Alamy

A good week for European biotech in the US, which began with Calliditas Therapeutics AB's Tarpeyo getting accelerated approval for immunoglobulin A nephropathy (IgAN), was rounded off by argenx N.V. getting the green light for Vyvgart in generalized myasthenia gravis (gMG).

First to the eagerly-anticipated approval by the US Food and Drug Administration of Vyvgart(efgartigimod) on 17 December for adults who...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

08 Aug 2025

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

07 Aug 2025

• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

07 Aug 2025

• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.